Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

126P Late line FOLFOX therapy after prior cisplatin-based regimen in advanced esophageal squamous cell carcinoma: A multi-institutional retrospective study

K. Shimozaki, K. Sugiyama, S. Koya, K. Shiraishi, M. Okada, Y. Matsubara, M. Furuta, S. Hirose, A. Komori,S. Mitani,S. Boku, T. Nishimura, K. Tsuchihashi,Y. Kito,A. Sugaya,T. Masuishi, T. Matsumoto,T. Tsuzuki,T. Yoshii,K. Hirata

Annals of Oncology（2022）

Cited 0|Views4
No score
Abstract
FOLFOX (5-fluorouracil, l-leucovorin and oxaliplatin [L-OHP]) is one of the treatment options for patients (pts) with advanced esophageal squamous cell carcinoma (aESCC). Because it is suggested that L-OHP showed activity in pts resistant to Cisplatin (CDDP), we evaluated the efficacy and safety of FOLFOX in pts who received prior CDDP-containing regimen.
More
Translated text
Key words
late line folfox therapy,squamous cell carcinoma,cisplatin-based,multi-institutional
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined